clinical trial · NCT05320692
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd.·phase3·active not recruiting·n = 423
Hepatocellular CarcinomaTACE+Camrelizumab+Apatinib mesylateTACE
brief summary
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
started
Aug 9, 2022
primary completion
Jul 30, 2026
completion
Jul 30, 2026
last updated
Dec 11, 2025
official title
A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol